GAM
VKTX icon

Gotham Asset Management’s Viking Therapeutics VKTX Stock Holding History

Gotham Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9M Sell
230,737
-30,041
-12% -$970K 0.02% 821
2026
Q1 		$8.49M Buy
260,778
+21,549
+9% +$693K 0.03% 732
2025
Q4 		$8.42M Buy
239,229
+69,546
+41% +$2.46M 0.03% 684
2025
Q3 		$4.46M Buy
+169,683
New +$5.06M 0.02% 811
2025
Q2 		– Sell
-24,500
Closed -$592K – 1752
2025
Q1 		$592K Buy
+24,500
New +$774K ﹤0.01% 1179

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Gotham Asset Management's VKTX Position: Q2 2026 in Review

Gotham Asset Management reduced its Viking Therapeutics (VKTX) stake by 12% in Q2 2026, selling an estimated $970K and leaving 230,737 shares worth $9M. The position accounts for 0.02% of the portfolio, ranked #821.

Gotham Asset Management first reported a position in VKTX in Q1 2025 and has held it in 5 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Gotham Asset Management held 230,737 shares of Viking Therapeutics worth $9M as of Q2 2026.
  • Gotham Asset Management sold 30,041 Viking Therapeutics shares in Q2 2026, an estimated $970K.
  • Viking Therapeutics made up 0.02% of Gotham Asset Management's portfolio in Q2 2026, its #821 holding.
  • Gotham Asset Management first reported a position in Viking Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.